389 related articles for article (PubMed ID: 17363521)
1. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors.
Baumgart E; Cohen MS; Silva Neto B; Jacobs MA; Wotkowicz C; Rieger-Christ KM; Biolo A; Zeheb R; Loda M; Libertino JA; Summerhayes IC
Clin Cancer Res; 2007 Mar; 13(6):1685-94. PubMed ID: 17363521
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy.
Kashibuchi K; Tomita K; Schalken JA; Kume H; Takeuchi T; Kitamura T
Int J Urol; 2007 Sep; 14(9):789-94. PubMed ID: 17760743
[TBL] [Abstract][Full Text] [Related]
3. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
[TBL] [Abstract][Full Text] [Related]
4. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
[TBL] [Abstract][Full Text] [Related]
5. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
6. Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies.
Bryan RT; Atherfold PA; Yeo Y; Jones LJ; Harrison RF; Wallace DM; Jankowski JA
J Pathol; 2008 Jun; 215(2):184-94. PubMed ID: 18393367
[TBL] [Abstract][Full Text] [Related]
7. Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer.
Syrigos KN; Harrington K; Waxman J; Krausz T; Pignatelli M
J Urol; 1998 Nov; 160(5):1889-93. PubMed ID: 9783980
[TBL] [Abstract][Full Text] [Related]
8. Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors.
Clairotte A; Lascombe I; Fauconnet S; Mauny F; Félix S; Algros MP; Bittard H; Kantelip B
Am J Clin Pathol; 2006 Jan; 125(1):119-26. PubMed ID: 16483000
[TBL] [Abstract][Full Text] [Related]
9. P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cells.
Mandeville JA; Silva Neto B; Vanni AJ; Smith GL; Rieger-Christ KM; Zeheb R; Loda M; Libertino JA; Summerhayes IC
BJU Int; 2008 Dec; 102(11):1707-14. PubMed ID: 18990147
[TBL] [Abstract][Full Text] [Related]
10. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
11. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma.
Fromont G; Rouprêt M; Amira N; Sibony M; Vallancien G; Validire P; Cussenot O
Eur Urol; 2005 Nov; 48(5):764-70. PubMed ID: 16126329
[TBL] [Abstract][Full Text] [Related]
12. Expression of classic cadherins type I in urothelial neoplastic progression.
Rieger-Christ KM; Cain JW; Braasch JW; Dugan JM; Silverman ML; Bouyounes B; Libertino JA; Summerhayes IC
Hum Pathol; 2001 Jan; 32(1):18-23. PubMed ID: 11172290
[TBL] [Abstract][Full Text] [Related]
13. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression.
Logullo AF; Nonogaki S; Pasini FS; Osório CA; Soares FA; Brentani MM
Oncol Rep; 2010 Feb; 23(2):313-20. PubMed ID: 20043090
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract.
Kashibuchi K; Tomita K; Schalken JA; Kume H; Yamaguchi T; Muto S; Horie S; Kitamura T
Eur Urol; 2006 May; 49(5):839-45; discussion 845. PubMed ID: 16426728
[TBL] [Abstract][Full Text] [Related]
15. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.
Shariat SF; Matsumoto K; Kim J; Ayala GE; Zhou JH; Jian W; Benedict WF; Lerner S
J Urol; 2003 Sep; 170(3):985-9. PubMed ID: 12913755
[TBL] [Abstract][Full Text] [Related]
16. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors.
Lascombe I; Clairotte A; Fauconnet S; Bernardini S; Wallerand H; Kantelip B; Bittard H
Clin Cancer Res; 2006 May; 12(9):2780-7. PubMed ID: 16675571
[TBL] [Abstract][Full Text] [Related]
17. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
Mahnken A; Kausch I; Feller AC; Krüger S
Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
[TBL] [Abstract][Full Text] [Related]
18. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
[TBL] [Abstract][Full Text] [Related]
19. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
[TBL] [Abstract][Full Text] [Related]
20. [New markers for pharmacological targeting in bladder cancer with lymph node metastasis].
Herrmann E; Eltze E; Köpke T; Bolenz C; Bierer S; Neumann J; Hertle L; Wülfing C
Aktuelle Urol; 2007 Sep; 38(5):392-7. PubMed ID: 17907066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
